Dear GCS Members,
We’re bringing you an important industry update following the CTA’s latest briefing with the Food Standards Agency (FSA) on CBD products (July 1, 2025).
🔍 What’s New?
The FSA has clarified safety expectations and labelling requirements for CBD products under the novel foods framework:
Key Updates Include:
THC Limits: Max 1mg of THC per container.
Label Must Include:
Daily intake advisory of 10mg for isolated CBD.
Statement on whether the product is an isolate or full-spectrum.
Age warning (not for under 18s).
Pregnancy warning.
Storage instructions.
Although the 10mg advisory is not enforceable by law, it’s considered best practice.
🚫 Reformulation Not Mandatory (Yet)
Companies are not required to reformulate immediately. However, doing so now can ease the path to full authorisation by autumn 2026.
🌱 Innovation Still Possible
Concerns that only tweaks to existing products would be allowed were addressed. New product SKUs will be reviewed using the same safety criteria—keeping the door open for innovation.
🛍️ Retailer Support on the Way
The FSA will release educational materials for retailers to help them understand and communicate these changes to customers.
📌 Why It Matters
Updating your product range and labels now allows you to:
Maintain market access.
Fast-track new compliant products.
Prepare for international market alignment.
✅ What Should You Do Now?
Audit your product line: Check THC levels and label compliance.
Plan reformulations: Especially for any products needing updates.
Watch for the isolated CBD consultation: GCS will notify you when this opens.
Engage with retailer training tools when they launch.
As always, GCS is here to support with tailored insights and SCI-led compliance strategies.
📥 Questions? Book a support call with us here
Make sure to sign up to and follow the Cannabis Trades Association (CTA): https://www.cannabistrades.org/
Stay safe and stay science-led,
— The GCS Team